Vetmedin Chew 1.25 mg chewable tablets for dogs.

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Pimobendan

제공처:

Boehringer Ingelheim Vetmedica GmbH

ATC 코드:

QC01CE90

INN (국제 이름):

Pimobendan

복용량:

1.25 mg/tablet

약제 형태:

Chewable tablet

처방전 유형:

POM: Prescription Only Medicine as defined in relevant national legislation

치료 영역:

pimobendan

승인 상태:

Authorised

승인 날짜:

2015-04-17

제품 특성 요약

Health Products Regulatory Authority
22 November 2019
CRN0090MR
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin Chew 1.25 mg chewable tablets for dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
​
One chewable tablet contains:
​
​
​
​
​
​
ACTIVE SUBSTANCE:
​
​
​
Pimobendan 1.25 mg
​
​
​
​
​
EXCIPIENTS:
​
​
​
For the full list of excipients, see section 6.1.
​
​
3 PHARMACEUTICAL FORM
Chewable tablet.
Brownish, oval, divisible tablet, scored on both sides.
The tablet can be divided into two equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from
dilated cardiomyopathy or valvular insufficiency (mitral
and/or tricuspid valve regurgitation).
(See also section 4.9).
For the treatment of dilated cardiomyopathy in the preclinical stage
(asymptomatic with an increase in left ventricular
end-systolic and end-diastolic diameter) in Doberman Pinschers
following echocardiographic diagnosis of cardiac disease (see
sections 4.4 and 4.5).
For the treatment of dogs with myxomatous mitral valve disease (MMVD)
in the preclinical stage (asymptomatic with a systolic
mitral murmur and evidence of increased heart size) to delay the onset
of clinical symptoms of heart failure (see sections 4.4
and 4.5).
4.3 CONTRAINDICATIONS
Do not use pimobendan in hypertrophic cardiomyopathies or in diseases
in which an improvement in cardiac output cannot be
achieved for functional or anatomical reasons (e.g. aortic stenosis).
Since pimobendan is metabolised mainly via the liver, it should not be
used in dogs with severe impairment of liver function.
(See also section 4.7).
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The product has not been tested in cases of asymptomatic DCM in
Dobermans with atrial fibrillation or sustained ventricular
ta